Page last updated: 2024-12-08
4'-azidocytidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
4'-azidocytidine: antiviral; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 457388 |
CHEMBL ID | 393857 |
CHEBI ID | 195574 |
MeSH ID | M0496337 |
Synonyms (27)
Synonym |
---|
HY-10444 |
478182-28-4 |
4'-azidocytidine |
4-amino-1-[(2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one |
R1479 , |
4'azc |
CHEMBL393857 |
r-1479 |
CHEBI:195574 |
4-amino-1-[(2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
CS-0362 |
DTXSID80332457 |
M71RA9DMGJ , |
4'-c-azidocytidine |
4-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-5-((imino-$l^5-azanylidene)amino)tetrahydrofuran-2-yl)pyrimidin-2-one |
cytidine, 4'-c-azido- |
4-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-5-((imino-lambda5-azanylidene)amino)tetrahydrofuran-2-yl)pyrimidin-2-one |
unii-m71ra9dmgj |
r 1479 |
4-amino-1-((2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one |
Q27283571 |
4-amino-1-((2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1h)-one |
A847966 |
F83782 |
AS-56761 |
4-amino-1-[(2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one |
AKOS037645067 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis." | ( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017) | 0.46 |
"This study concluded that FNC is safe to use though higher concentration shows slight toxicity." | ( Safety Assessment of a Nucleoside Analogue FNC (2'-deoxy-2'- β-fluoro-4'-azidocytidine ) in Balb/c Mice: Acute Toxicity Study. Acharya, A; Delu, V; Fayzullina, D; Kaushalendra, K; Kumar, N; Kumar, S; Mohanta, SP; Patel, AK; Rachana, K; Shukla, A; Singh, RK; Tiwari, R; Ulasov, I; Yadav, L, 2023) | 1.14 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The present study was undertaken to evaluate the absolute oral bioavailability of FNC in rats and the pharmacokinetic properties of FNC after intragastric administration of single and multiple doses in rats and dogs." | ( Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies. Chang, J; Chen, X; Cheng, T; Dong, L; Guo, M; Guo, X; Jiang, J; Peng, Y; Wang, Q; Zhang, J; Zhang, Y, 2014) | 0.67 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-infected treatment-naive patients." | ( R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML, 2008) | 0.35 |
"6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R." | ( Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G, 2009) | 0.35 |
Bioavailability
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
N-glycosyl compound | A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (62)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID573109 | Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID536905 | Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay | 2010 | Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22 | 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. |
AID475235 | Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV 1b | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8 | Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. |
AID348494 | Cytotoxicity against human HuH7 cells by XTT assay | 2008 | Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19 | New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection. |
AID555947 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 5 passages at 4 uM by quantitative RT-PCR relative to wild type virus | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID573111 | Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID1200154 | Antiviral activity against Respiratory syncytial virus subgenomic replicon system in 395 HeLa cells assessed as reduction in viral replication after 7 days by renilla luciferase assay | 2015 | Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4 | Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. |
AID555953 | Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID547287 | Selectivity ratio of EC90 for Hepatitis C virus harboring NS5B polymerase S96T mutant gene to EC90 for HCV harboring wild type NS5B polymerase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID514138 | Antiviral activity against HCV Con 1 by subgenomic replicon assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14 | Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication. |
AID353350 | Cytotoxicity against human 2209-23 cells assessed as cell viability by WST-1 assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine. |
AID475233 | Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8 | Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. |
AID547286 | Antiviral activity against Hepatitis C virus harboring NS5B polymerase S96T mutant gene infected in human lunet cells by luciferase-based replicon assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID520336 | Cytotoxicity against human HuH7 cells | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. |
AID411722 | Cytotoxicity against human 2209-23 cells by WST1 cell ciability assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine. |
AID573112 | Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID348493 | Antiviral activity against HCV subtype 1a in Huh7 cells assessed as reduction of viral RNA replication | 2008 | Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19 | New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection. |
AID573106 | Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID306693 | Cytotoxicity against human 2209-23 cells at 20 uM | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID555946 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 7 passages at 15 uM by quantitative RT-PCR relative to wild type virus | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID555948 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected at 0.5 uM by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID125167 | In vitro Cytotoxic concentration in mock-infected A3.01 cells. | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides. |
AID353351 | Antiproliferative activity against human 2209-23 cells assessed as [3H]thymidine incorporation by scintillation proximity assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine. |
AID547285 | Antiviral activity against Hepatitis C virus harboring wild-type NS5B infected in human lunet cells by luciferase-based replicon assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID306696 | Cytotoxicity against human 2209-23 cells | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID306697 | Cytostatic activity against human 2209-23 cells | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID547283 | Antiviral activity against Hepatitis C virus harboring NS5B polymerase S282T mutant gene infected in human HuH7 cells by luciferase-based replicon assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID555955 | Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID573107 | Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID536906 | Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay | 2010 | Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22 | 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. |
AID555945 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 5 passages at 4 uM by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID306698 | Inhibition of HCV 1b BK NS5B570 RNA polymerase | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID573110 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID547090 | Antiviral activity against Hepatitis C virus harboring NS5B polymerase S96T/N142T mutant gene infected in human HuH7 cells by luciferase-based replicon assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID7700 | Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides. |
AID1497242 | Antiviral activity against Dengue virus 2 infected in human PBMC after 24 hrs post infection by plaque assay | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13 | Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase. |
AID514139 | Cytotoxicity against human HuH7 cells | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14 | Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication. |
AID555954 | Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID411723 | Antiproliferative activity against human 2209-23 cells by [3H]thymidine incorporation scintillation proximity assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine. |
AID306695 | Antiviral activity against HCV 1b replicon in human 2209-23 cells | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID658633 | Competitive inhibition of Hepatitis C virus NS5B RNA-dependent RNA polymerase | 2012 | Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10 | Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. |
AID428151 | Antiviral activity against HCV Con1 GT1b by replicon assay | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479). |
AID353349 | Antiviral activity against HCV 1b infected in human 2209-23 cells by replicon assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine. |
AID573105 | Cytotoxicity against human HuH6 cells after 3 days by MTT assay | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID573108 | Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. |
AID555949 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected at 0.1 uM by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID555944 | Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 7 passages at 15 uM by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID547284 | Selectivity ratio of EC90 for Hepatitis C virus harboring NS5B polymerase S282T mutant gene to EC90 for Hepatitis C virus harboring wild-type NS5B polymerase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID555950 | Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID1200155 | Cytotoxicity against human HeLa cells assessed as cell viability by CellTiter-Glo luminescent assay | 2015 | Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4 | Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. |
AID411721 | Antiviral activity against Hepatitis C virus infected human 2209-23 cells by genotype 1b replicon assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine. |
AID475234 | Cytotoxicity against human HuH7 cells after3 days by MTT assay | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8 | Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. |
AID555951 | Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID1497244 | Inhibition of human full length POLRMT using 32P-RNA primer/DNA template assessed as single nucleotide incorporation rate at 500 uM by SDS-PAGE analysis relative to CTP | 2018 | Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13 | Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase. |
AID520335 | Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. |
AID571733 | Antiviral activity against Hepatitis C virus infected in cells assessed as log reduction in viral RNA level from baseline at 4500 mg administered BID for 14 days by Replicon Assays | 2008 | Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12 | 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors. |
AID555952 | Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. |
AID125169 | In vitro Cytotoxic concentration in mock-infected A3.01 cells - 100% toxicity. | 1992 | Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8 | Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides. |
AID547282 | Antiviral activity against Hepatitis C virus harboring wild-type NS5B infected in human HuH7 cells by luciferase-based replicon assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. |
AID306691 | Antiviral activity against HCV 1b replicon in human 2209-23 cells assessed as inhibition of viral replication at 20 uM | 2007 | Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9 | Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. |
AID353348 | Inhibition of HCV NS5B polymerase-mediated RNA synthesis | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine. |
AID536907 | Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay | 2010 | Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22 | 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (33)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.03) | 18.2507 |
2000's | 18 (54.55) | 29.6817 |
2010's | 13 (39.39) | 24.3611 |
2020's | 1 (3.03) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (6.06%) | 5.53% |
Reviews | 3 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (84.85%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |